The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients
Open accessAbstract
Autologous induced pluripotent stem cells (iPSCs) constitute an unlimited cell source for patient-specific cell-based organ repair strategies. However, their generation and subsequent differentiation into specific cells or tissues entail cell line-specific manufacturing challenges and form a lengthy process that precludes acute treatment modalities. These shortcomings could be overcome by using prefabricated allogeneic cell or tissue products, but the vigorous immune response against histo-incompatible cells has prevented the successful implementation of this approach. Here we show that both mouse and human iPSCs lose their immunogenicity when major histocompatibility complex (MHC) class I and II genes are inactivated and CD47 is over-expressed. These hypoimmunogenic iPSCs retain their pluripotent stem cell potential and differentiation capacity. Endothelial cells, smooth muscle cells, and cardiomyocytes derived from hypoimmunogenic mouse or human iPSCs reliably evade immune rejection in fully MHC-mismatched allogeneic recipients and survive long-term without the use of immunosuppression. These findings suggest that hypoimmunogenic cell grafts can be engineered for universal transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These gene-edited iPSCs could differentiate into endothelial cells and cardiomyocytes that demonstrated long-term survival in humanized mouse models without any immunosuppression.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [118]
The cited source says what the claim attributes to it.
In the citing paper
“Overexpression of CD47 has also been successfully implemented to mitigate innate immune responses after HLA deletion.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D. J., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,578
Humanized mice in translational biomedical research
Shultz, L. D., Ishikawa, F., & Greiner, D. L. (2007) · Nature reviews. Immunology · doi:10.1038/nri2017 · Cited by 1,393
Humanized mice in translational biomedical research
Shultz, L. (2007) · The Mouseion at the JAXlibrary (Jackson Laboratory) · Cited by 1,036
Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts
Shiba, Y., Gomibuchi, T., Seto, T., Wada, Y., Ichimura, H., Tanaka, Y., Ogasawara, T., Okada, K., Shiba, N., Sakamoto, K., et al. (2016) · Nature · doi:10.1038/nature19815 · Cited by 840
Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1
Melkus, M. W., Estes, J. D., Padgett‐Thomas, A., Gatlin, J., Denton, P. W., Othieno, F. A., Wege, A. K., Haase, A. T., & Garcia, J. V. (2006) · Nature Medicine · doi:10.1038/nm1431 · Cited by 653
Self-citationHLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
Gornalusse, G. G., Hirata, R. K., Funk, S. E., Riolobos, L., Lopes, V. S., Manske, G., Prunkard, D., Colunga, A. G., Hanafi, L.-A., Clegg, D. O., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3860 · Cited by 639
Fetomaternal immune cross-talk and its consequences for maternal and offspring's health
Arck, P., & Hecher, K. (2013) · Nature Medicine · doi:10.1038/nm.3160 · Cited by 609
Wunderlich, M., Chou, F.-S., Link, K. A., Mizukawa, B., Perry, R. L., Carroll, M., & Mulloy, J. C. (2010) · Leukemia · doi:10.1038/leu.2010.158 · Cited by 415
Chang, C., Fontes, J., Peterlin, M., & Flavell, R. (1994) · Journal of Experimental Medicine · doi:10.1084/jem.180.4.1367 · Cited by 352
Gyöngyösi, M., Wojakowski, W., Lemarchand, P., Lunde, K., Tendera, M., Bartunek, J., Marbán, E., Aßmus, B., Henry, T. D., Traverse, J. H., et al. (2015) · Circulation Research · doi:10.1161/circresaha.116.304346 · Cited by 313
Cited by
Sorted by citations
Items 401–500 of 758
CRISPR-Cas9 immune-evasive hESCs are rejected following transplantation into immunocompetent mice
Frederiksen, H. R. S., Glantz, A., Vøls, K. K., Skov, S., Tveden‐Nyborg, P., Freude, K., & Doehn, U. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1403395 · Cited by 9
Regenerative medicine in cardiovascular disease
Goto, T., Nakamura, Y., Ito, Y., & Miyagawa, S. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2024.09.004 · Cited by 9
Lei, Q., Deng, H., & Sun, S. (2025) · Life Medicine · doi:10.1093/lifemedi/lnaf002 · Cited by 9
Thongsin, N., & Wattanapanitch, M. (2021) · Stem Cell Research · doi:10.1016/j.scr.2021.102551 · Cited by 9
Pluripotent stem cell-based cell therapies: Current applications and future prospects
Wang, G., Heimendinger, P., Ramelmeier, R. A., & Wang, W. (2022) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2022.100390 · Cited by 11
Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies
Zhu, I., Piraner, D. I., & Roybal, K. T. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0962 · Cited by 9
Can pluripotent/multipotent stem cells reverse Parkinson’s disease progression?
Wu, Y., Meng, X., Cheng, W., Yan, Z., Li, K., Wang, J., Jiang, T., Zhou, F., Wong, K., Zhong, C., et al. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1210447 · Cited by 9
Modeling the human heart ex vivo—current possibilities and strive for future applications
Kałużna, E. M., Nadel, A., Zimna, A., Rozwadowska, N., & Kolanowski, T. J. (2022) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.3335 · Cited by 9
Genetically Modified Humans: The X-Men of Scientific Research
Straiton, J. (2019) · BioTechniques · doi:10.2144/btn-2019-0056 · Cited by 11
Cherkashova, E. A., Leonov, G. E., Namestnikova, D. D., Соловьева, А. А., Gubskiy, I. L., Bukharova, T. B., Губский, Л. В., Goldstein, D. V., & Yarygin, K. N. (2020) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-020-04754-4 · Cited by 9
Emerging cell therapy for biliary diseases
Kurial, S. N. T., & Willenbring, H. (2021) · Science · doi:10.1126/science.abg3179 · Cited by 10
Efficient Vascular and Neural Engraftment of Stem Cell–Derived Islets
Thorngren, J., Brboric, A., Vasylovska, S., Hjelmqvist, D. T., Westermark, G. T., Saarimäki‐Vire, J., Kvist, J., Balboa, D., Otonkoski, T., Carlsson, P., et al. (2024) · Diabetes · doi:10.2337/db23-0123 · Cited by 9
Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
Teo, P. Y., Jung, Y., Quach, D. H., Koh, J., Ong, R., Goh, A. X., Tan, A. S. M., Ng, C. H., Seh, C. C., Tan, K. W., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-1001 · Cited by 8
Zhang, Q., Xia, C., Weng, Q., Zhang, L., Wang, Y., Liu, Y., Zheng, X., Lin, Y., Chen, Y., Shen, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1504459 · Cited by 8
Yi, L., Woon, H. R., Saw, G., Zeng, L., Tan, E., & Zhou, Z. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00771 · Cited by 8
iPSC modification strategies to induce immune tolerance
Hong, Z., Zhao, Y. F., Pahlavan, S., Wang, X., Han, S., Wang, K., & Wang, K. (2025) · Life Medicine · doi:10.1093/lifemedi/lnaf016 · Cited by 9
Hu, X., Tediashvili, G., Gravina, A., Stoddard, J., McGill, T. J., Connolly, A. J., Deuse, T., & Schrepfer, S. (2025) · Nature Communications · doi:10.1038/s41467-025-58774-7 · Cited by 9
Self-citationProspects and limitations of NK cell adoptive therapy in clinical applications
Deng, Y., Wu, C. H., Na, J., Tang, J., Qin, S., Zhang, Z., & Zhong, L. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10273-3 · Cited by 8
From Bench to Bedside: Emerging Paradigms in CAR‐T Cell Therapy for Solid Malignancies
Chen, Y., Ren, R., Yan, L., Zhou, Y., Sun, R., Song, H., Yan, H., & Li, Y. (2025) · Advanced Science · doi:10.1002/advs.202505822 · Cited by 9
Hypoimmune stem cells and islets: hype or a true breakthrough in diabetes treatment?
Shalaby, K. E., & Abdelalim, E. M. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00786-8 · Cited by 10
Synthetic Biology Technologies And Genetically Engineering Strategies For Enhanced Cell Therapeutics
Li, S., Tang, H., Li, C., Ma, J., Ali, M., Dong, Q. R., Wu, J., Hui, Y., & Sun, C. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10454-5 · Cited by 9
Banovic, M. D., Poglajen, G., Vrtovec, B., & Ristić, A. D. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9120429 · Cited by 9
Hang, S., Wang, N., & Sugimura, R. (2023) · Differentiation · doi:10.1016/j.diff.2023.01.001 · Cited by 8
Immortal orexin cell transplants restore motor-arousal synchrony during cataplexy
Pintwala, S. K., Fraigne, J. J., Belsham, D. D., & Peever, J. H. (2023) · Current Biology · doi:10.1016/j.cub.2023.03.077 · Cited by 9
Generation of the NeoThy mouse model for human immune system studies
Rio, N. M. D., Huang, L., Murphy, L., Babu, J. S., Daffada, C. M., Haynes, W. J., Keck, J., Brehm, M. A., Shultz, L. D., & Brown, M. E. (2023) · Lab Animal · doi:10.1038/s41684-023-01196-z · Cited by 9
Human PSC-derived cardiac cells and their products: therapies for cardiac repair
Menasché, P. (2023) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2023.08.002 · Cited by 9
Stem Cell Therapy for Liver Diseases: Current Perspectives
Wang, J., Li, Q., Li, W., Méndez‐Sánchez, N., Liu, X., & Qi, X. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2812359 · Cited by 9
Engineering pluripotent stem cells with synthetic biology for regenerative medicine
Mao, Y., Wang, S., Yu, J., & Li, W. (2024) · Medical Review · doi:10.1515/mr-2023-0050 · Cited by 8
Beta cells deficient for Renalase counteract autoimmunity by shaping natural killer cell activity
Bode, K., Wei, S., Gruber, I., Li, J., Kissler, S., & Peng, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1403752 · Cited by 8
Ortega-Gascó, A., Percopo, F., Font-Guixe, A., Ramos-Bartolome, S., Cami-Bonet, A., Magem-Planas, M., Fabrellas-Monsech, M., Esquirol-Albala, E., Goulet, L., Fornos-Zapater, S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157262 · Cited by 9
Benabdallah, B., Désaulniers-Langevin, C., Goyer, M.-L., Colas, C., Maltais, C., Li, Y.-Y., Guimond, J., Tremblay, J., Haddad, É., & Beauséjour, C. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0452 · Cited by 9
Pancreas transplant versus islet transplant versus insulin pump therapy: in which patients and when?
Tamburrini, R., & Odorico, J. S. (2021) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000857 · Cited by 8
Rossbach, B., Hariharan, K., Mah, N., Oh, S.-J., Volk, H., Reinke, P., & Kurtz, A. (2022) · Cells · doi:10.3390/cells11081328 · Cited by 8
Advances in Cardiac Tissue Engineering
Kitsuka, T., Takahashi, F., Reinhardt, J. W., Watanabe, T., Ulziibayar, A., Yimit, A., Kelly, J. M., & Shinoka, T. (2022) · Bioengineering · doi:10.3390/bioengineering9110696 · Cited by 8
Bode, K., MacDonald, T. L., Stewart, T., Mendez, B., Cai, E. P., Morrow, N., Lee, Y., Peng, Y., & Kissler, S. (2023) · Diabetes · doi:10.2337/db23-0030 · Cited by 8
Chen, X. X., Laurent, A. E., Liao, Z., Jaccoud, S., Abdel-Sayed, P., Flahaut, M., Scaletta, C., Raffoul, W., Applegate, L. A., & Hirt‐Burri, N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092334 · Cited by 8
Mouse Pluripotent Stem Cell Differentiation Under Physiological Oxygen Reduces Residual Teratomas
Millman, J. R., Tan, J. H., & Colton, C. K. (2021) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-021-00687-8 · Cited by 7
Non-human primate studies for cardiomyocyte transplantation—ready for translation?
von Bibra, C., & Hinkel, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1408679 · Cited by 8
Kapetanovic, E., Weber, C. R., Bruand, M., Pöschl, D., Kucharczyk, J., Hirth, E., Dietsche, C. L., Khan, R. A., Wagner, B., Belli, O., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01255-x · Cited by 8
Wei, Y., Geng, X., You, Q., Zhang, Y., Cao, F., Narayanan, G., Nguyen, T. M., Chen, X. S., Zhang, J. J., & Ye, L. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.04.017 · Cited by 7
Hypoimmunogenic pluripotent stem cells: A game-changer in cell-based regenerative medicine
Sarabi, P. A., Rismani, E., Shabanpouremam, M., Hendi, Z., Nikoubin, B., Rahimi, S., Taleb, M., Khosravi, A., Zarrabi, A., Hassan, M., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115134 · Cited by 7
Diminished immune cell adhesion in hypoimmune ICAM-1 knockout human pluripotent stem cells
Saha, S., Haynes, W. J., Seo, J., Rio, N. M. D., Young, E. E., Zhang, J., Holm, A. M., Pimentel, M., Flannagan, L. E., Huang, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62568-2 · Cited by 7
Bangolo, A., Amoozgar, B., Zhang, L., Gill, S. K., Milolo, D. L., Kankonde, J. N., Batakamuna, C. M., Tassan, R., Cho, C., Bukasa-Kakamba, J., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13082022 · Cited by 8
Oubari, H., Berkane, Y., Jeljeli, M. M., Lellouch, A. G., & Smadja, D. M. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10968-8 · Cited by 7
Immunocompatibility in transplantation: adapting to a changing therapeutic landscape
Güell-Alonso, R., Cabrera-Pérez, R., & Vives, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1648534 · Cited by 7
Brown, M. E., Barra, J. M., Pina, M., Proia, J., Brusko, T. M., & Russ, H. A. (2025) · Science Advances · doi:10.1126/sciadv.adx9755 · Cited by 8
Stealth designs to overcome allorejection in engineered cell therapy
Li, Y.-R., Chen, Y., & Yang, L. (2026) · Trends in Immunology · doi:10.1016/j.it.2026.02.008 · Cited by 9
Strategies and mechanisms of precision genome engineering: From gene editing to genome writing
Huang, K., Tian, J., Zhao, W., Zhang, S., Xiang, L., Yang, M., Ls, L., Huang, Y., Zhang, N., Sun, L., et al. (2026) · iMetaOmics. · doi:10.1002/imo2.70115 · Cited by 8
Carlier, S., Depuydt, E., Hecke, L. L. V., Martens, A., Saunders, J., & Spaas, J. H. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1282697 · Cited by 7
Liu, J., Ji, Z., He, Q., Chen, H., Xu, X., Mei, Q., Hu, Y., & Zhang, H. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106683 · Cited by 9
Lee, J. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081825 · Cited by 7
At Home among Strangers: Is It Possible to Create Hypoimmunogenic Pluripotent Stem Cell Lines?
Bogomiakova, M. E., Валерьевич, Е. А., & Lagarkova, M. A. (2019) · Molecular Biology · doi:10.1134/s0026893319050042 · Cited by 7
Cardiac Regeneration Using Pluripotent Stem Cells and Controlling Immune Responses
Ichimura, H., Chino, S., & Shiba, Y. (2023) · Heart Lung and Circulation · doi:10.1016/j.hlc.2022.12.014 · Cited by 7
Kishino, Y., Tohyama, S., Morita, Y., SOMA, Y., Tani, H., Okada, M., Kanazawa, H., & Fukuda, K. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.10.433 · Cited by 7
Sharma, D., Sharma, A., Hu, L., Chen, T.-A., Voon, S., Bayless, K. J., Goldman, J., Walsh, A. J., & Zhao, F. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.07.023 · Cited by 7
Parkinson’s disease grafts benefit from well-timed growth factor
Studer, L., & Tabar, V. S. (2020) · Nature · doi:10.1038/d41586-020-01486-3 · Cited by 7
Jiang, L., Liang, J., Huang, W. C., Wu, Z., Paul, C., & Wang, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207662 · Cited by 7
Shiba, Y. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0755 · Cited by 7
Liu, W., Jiang, H., Chen, J., Tian, Y., He, Y. Z., Jiao, Y., Guan, Y., Jia, Z., Wu, Y., Huang, C., et al. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101372 · Cited by 6
Zhang, J., Tabima, D. M., Vereide, D. T., Zeng, W., Albano, N. J., Lyon, S. M., Nicksic, P. J., Shaffrey, E. C., George, R. E., Probasco, M. D., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102002 · Cited by 6
Hussein, A., Hashish, E. A. A., Abd-Elghaffar, B. A., & Elliethey, N. S. (2025) · BMC Nursing · doi:10.1186/s12912-025-02759-w · Cited by 9
Selective agonists of KIR and NKG2A to evade missing self response of natural killer cells
Hiura, S., Kuwasaki, Y., Nishikawa, Y., Kimura, T., Yoshida, S., Nakayama, M., Makino, T., & Ueno, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-18394-z · Cited by 6
Engineering hypoimmune stem cell-derived beta cells
Licht, B. J. M., Duffy, G. P., & Levey, R. E. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04745-0 · Cited by 8
Role of Cell-Based Therapies in T2D
Ashe, S., & Hebrok, M. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151432 · Cited by 6
Roslan, F. F., Yu, Y., Ooi, G., Then, K., Then, K. Y., Cheong, S., Guo, Z., Patar, M. N. A. A., & Tan, J. J. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5438 · Cited by 6
Boonkaew, B., Suwanpitak, S., Pattanapanyasat, K., Sermsathanasawadi, N., & Wattanapanitch, M. (2022) · Cell and Tissue Research · doi:10.1007/s00441-022-03576-2 · Cited by 6
Direct Reprogramming of Different Cell Lineages into Pancreatic β-Like Cells
Colarusso, J. L., & Zhou, Q. (2022) · Cellular Reprogramming · doi:10.1089/cell.2022.0048 · Cited by 6
Cell Inertia: Predicting Cell Distributions in Lung Vasculature to Optimize Re-endothelialization
Chan, J. K. D., Chadwick, E. A., Taniguchi, D., Ahmadipour, M., Suzuki, T., Romero, D. A., Amon, C. H., Waddell, T. K., Karoubi, G., & Bazylak, A. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.891407 · Cited by 6
Lee, N. K., Myeong, S. H., Hwang, J. W., Sa, J. K., Son, H. J., Kim, H., Jang, H., Chang, J. W., & Na, D. L. (2022) · Biomedicines · doi:10.3390/biomedicines10081882 · Cited by 7
Challenges of cell therapies for retinal diseases
Monville, C., Morizur, L., & M’Barek, K. B. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.09.004 · Cited by 6
Kuzma-Hunt, A. G., Shah, V., DiMarco, S., Russell, K. A., Betts, D. H., & Koch, T. G. (2023) · Stem Cells and Development · doi:10.1089/scd.2022.0300 · Cited by 6
Dadheech, N., Cuesta‐Gomez, N., Jasra, I. T., Verhoeff, K. K., Marfil‐Garza, B. A., Mouhammed, O., & Shapiro, A. M. J. (2022) · Journal of Immunology and Regenerative Medicine · doi:10.1016/j.regen.2022.100064 · Cited by 6
Induced Pluripotent Stem Cells for Clinical Use
Vanneaux, V. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88878 · Cited by 6
Genetic ablation of adhesion ligands averts rejection of allogeneic immune cellsPreprint
Hammer, Q., Perica, K., van Ooijen, H., Mbofung, R. M., Momayyezi, P., Varady, E., Martin, K. E., Pan, Y., Jelcic, M., Groff, B. C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.09.557143 · Cited by 6
Hypoimmunogenic hPSC-derived cardiac organoids for immune evasion and heart repairPreprint
Silver, S. E., Howells, A. R., Arhontoulis, D. C., Randolph, L. N., Hyams, N. A., Barrs, R. W., Li, M., Kerr, C. M., Robino, R. A., Morningstar, J. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.09.648007 · Cited by 6
Stem cell therapy: A promising therapeutic approach for skeletal muscle atrophy
Wang, Y., Chen, Z., Shen, Y., Wang, K., Han, Y.-M., Zhang, C., Yang, X.-M., & Chen, B. (2025) · World Journal of Stem Cells · doi:10.4252/wjsc.v17.i2.98693 · Cited by 6
Naffaa, M. M. (2025) · Regenerative medicine reports . · doi:10.4103/regenmed.regenmed-d-25-00013 · Cited by 5
Yang, J., Yue, T., He, J. X., Xiong, S., Luo, Y., & Hou, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1600604 · Cited by 5
Induced Pluripotent Stem Cell-Based Cancer Immunotherapy: Strategies and Perspectives
Xun, X., Hao, J., Cheng, Q., & Gao, P. (2025) · Biomedicines · doi:10.3390/biomedicines13082012 · Cited by 5
CD47/SIRPα pathways: Functional diversity and molecular mechanisms
Bhardwaj, N., Chandra, H. M., Singh, A., & Babu, R. (2025) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v16.i3.108045 · Cited by 5
Immune modulation for β-cell replacement in type 1 diabetes
Yang, Q., Song, Y., Markmann, J. F., & Lei, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1785523 · Cited by 5
Clinical translational research on stem cell products: prospects and challenges
Chen, S., ZHANG, L., Ren, Y., Bai, X., Wei, X., Chai, M., 崔苏甦, Zhao, X., & Deng, H. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02582-y · Cited by 17
Research progress in stem cell therapy for Wilson disease
Xiong, X., Gao, C., Meng, X., Liu, A., Gong, X., & Sun, Y. J. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2024.03.005 · Cited by 5
Vascular and immune interactions in islets transplantation and 3D islet models
Migliorini, A., & Nostro, M. C. (2024) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2024.102237 · Cited by 5
Farag, A. A. G., Hendawy, H. A., Emam, M. H., Hasegawa, M., Mandour, A. S., & Tanaka, R. (2025) · Biomolecules · doi:10.3390/biom15030371 · Cited by 5
Synthetic genomics for curing genetic diseases
Grazioli, S., & Petris, G. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.02.002 · Cited by 5
The HIP mouse and all of its organs are completely invisible to allogeneic immune cells
Hu, X.-M., White, K., Olroyd, A. G., Wang, C., Caruso, C. B., Gattis, C., Chi, Y., Connolly, A. J., Deuse, T., & Schrepfer, S. (2024) · iScience · doi:10.1016/j.isci.2024.111492 · Cited by 5
Self-citationNiedźwiedzka-Rystwej, P., Wołącewicz, M., Cywoniuk, P., Klak, M., & Wszoła, M. (2020) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-020-00578-2 · Cited by 4
Shin, S., Song, E., Kwon, Y., Oh, S., Park, H., Kim, N.-H., & Roh, E. (2020) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2020.05.008 · Cited by 4
An, J.-H., Koh, H., Ahn, Y., Kim, J., Han, A., Lee, J. Y., Kim, S., & Lee, J.-H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.936584 · Cited by 5
Universal and hypoimmunogenic pluripotent stem cells for clinical usage
Sung, T., Maitiruze, K., Pan, J., Gong, J., Bai, Y., Pan, X., & Higuchi, A. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.02.014 · Cited by 5
Keeping the Heart Healthy: The Role of Exercise in Cardiac Repair and Regeneration
Jiang, J., Ni, L., Zhang, X., Chatterjee, E., Lehmann, H. I., Li, G., & Xiao, J. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0301 · Cited by 5
Ji, T.-T., Niu, S., Fang, M.-H., Xu, L., Wang, X., Zou, J., Xu, F., Zhang, M., Niu, R., Wu, J., et al. (2023) · Cell Proliferation · doi:10.1111/cpr.13471 · Cited by 5
Modern Tools of Genome Engineering and Their Applications
Kaur, R., Singh, A. K., Singh, D. K., & Singh, S. (2023) · Springer eBooks · doi:10.1007/978-981-99-3126-2_9 · Cited by 5
Update on Mesenchymal and Induced Pluripotent Stem Cells
Al‐Anazi, K. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.77857 · Cited by 5
Improving the safety of iPSC-derived T cell therapy
Ando, M., Kinoshita, S., Furukawa, Y., Ando, J., Nakauchi, H., & Brenner, M. (2022) · Molecular Players in iPSC Technology · doi:10.1016/b978-0-323-90059-1.00010-5 · Cited by 3
Generation of a homozygous CIITA knockout iPS cell line using the CRISPR-Cas9 system
Romano, E., Trionfini, P., Giampietro, R., Benigni, A., & Tomasoni, S. (2021) · Stem Cell Research · doi:10.1016/j.scr.2021.102580 · Cited by 4
Batty, L. D., Park, J., Qin, L., Riaz, M., Lin, Y., Xu, Z., Gao, X., Li, X., Lopez, C. A., Zhang, W., et al. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.12.033 · Cited by 4
Li, B., Zhang, X., Fang, Y., Chen, M., Li, Q., Zeng, Y., Ren, C., Wang, C., Lv, Y., Lu, J., et al. (2025) · Cell Proliferation · doi:10.1111/cpr.70007 · Cited by 4
Wu, C., Li, X., Wang, H., Xiao-ya, Y., & Liu, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680179 · Cited by 4
Metadata
- Authors
- Deuse, T., Hu, X., Gravina, A., Wang, D., Tediashvili, G., De, C., Thayer, W. O., Wahl, A., Garcia, J. V., Reichenspurner, H., Davis, M. M., Lanier, L. L., & Schrepfer, S.
- Affiliations
- University of California, San Francisco (US)
- Universität Hamburg (DE)
- University of North Carolina at Chapel Hill (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Schrepfer, Sonja
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2019-02-18
- Volume
- 37
- Issue
- 3
- Pages
- 252-258
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC6419516
- OpenAlex
- W2911604931
- Cited by
- 758
- References
- 31
- Citations by year
- 2026: 98 · 2025: 102 · 2024: 102 · 2023: 113 · 2022: 94 · 2021: 97 · 2020: 106 · 2019: 46
- FWCI
- 28.36
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-09-16)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL140236)
- National Institute of Mental Health (R01MH108179)
- National Institute of Allergy and Infectious Diseases (R01AI068129, R01AI111899, R01AI123010, U19AI057229)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Transplantation › Organ and Tissue Transplantation Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- induced pluripotent stem cells, immune rejection, allogeneic transplantation, MHC mismatch, endothelial cells, smooth muscle cells, cardiomyocytes, immunosuppression-free transplantation
- MeSH terms
- Animals, Cell Differentiation, Graft Rejection, HLA Antigens, Humans, Transplantation, Homologous, Histocompatibility Antigens Class I, Myocytes, Cardiac, Mice, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
